Here’s what you need to know.
1. The company’s GI products include: Linzess, Viberzi, Asacol/Delzicol, Carafate/Sulcrate, Canasa/Salofalk and Zenpep.
2. In the third quarter, Allergan reported revenues of $431.4 million in 2016 compared to $398.6 million in 2015.
3. All Allergan GI products except Asacol/Delzicol reported positive growth.
More articles on gastroenterology/endoscopy:
Genetic Technologies, University of Melbourne collaborate on CRC risk assessment tool: 3 notes
Do financial incentives promote patient adherence to CRC screening? 5 study insights
GI leader to know: Dr. Carl Gessner of LeBauer HealthCare
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
